申请人:Boehringer Ingelheim International GmbH
                            
                            
                                公开号:US20130150401A1
                            
                            
                                公开(公告)日:2013-06-13
                            
                            The present invention relates to compounds of formula I,
wherein R
1
, L
P
, L
Q
, X, A, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
                            本发明涉及公式I的化合物,
其中R
1
,LP,LQ,X,A和n如申请中所定义,具有有价值的药理特性,特别是结合GPR119受体并调节其活性。